Vaxart reports Q2 revenue of $39.2M, falling short of expectations by $26.3M despite matching EPS estimates.
Vaxart reported a GAAP earnings per share of $0.02, aligning with estimates, but revenue reached only $39.2M, missing projections by $26.3M. The shortfall highlights challenges in scaling commercial operations despite meeting profitability metrics.
Analysts had anticipated stronger revenue growth following prior quarter performance, where revenue totaled 26.3M. The company’s revenue trajectory has been volatile, reflecting uneven demand for its oral vaccine platform.
Shares showed limited movement in after-hours trading as investors weighed the mixed results against broader sector trends.